ChromoCure to Begin Live Animal Trials for Clinical Therapeutics Research With University Research Programs
2010年3月25日 - 10:00PM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) -- ChromoCure announced today
an expansion of its Cancer Research initiatives with Live Animal
Therapeutics Research collaboration with selected University Cancer
Research Programs.
This Collaborative Research Initiative will be a strategic
expansion of the Company's "Project Boveri: Find the Cure," adding
the ability to monitor hourly chromosome aneuploidy progression.
The company's technology and related research opens the way for
non-invasive and non-toxic solutions to cancer therapeutics and
disease eradication.
The Company believes its cancer detection and progression
measurement capabilities provide unprecedented monitoring and
objective measurement of therapeutic research and results.
The Company's focus on cancer research has been validated and
further underscored by recent major clinical publications that both
validate ChromoCure's chromosomal (aneuploidy) theory of cancer and
establish the company's detection approach as the forefront of both
cancer detection and research.
The Company's proprietary technology has proven accurate in the
measurement of the unique genomic characteristic found in 100% of
all cancers and to have an effective accuracy of 100% for all
cancers at all stages. ChromoCure's scanner technologies include
proprietary designs, processes, and algorithms centered on
chromosomal imbalance. They provide the foundation for significant
advantages in delivering important results in diagnosis, therapy
and cure.
The Company invites University collaboration through its
"Project Boveri: Find the Cure" initiative.
The Company will soon announce important additions and changes
to its operations and research in the areas of therapeutics and
disease eradication.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection
systems and related therapeutic technologies. The Company's
proprietary CS200 Chromosomal Scanner has been proven accurate and
efficient in the measurement of the unique genomic characteristic
found in 100% of all cancers and never found in normal cells. The
Company's detection technology has an effective accuracy of 100%
for all cancers at all stages. The Company believes its technology
will become the worldwide gold standard for cancer detection,
progression measurement, and research for both therapy and cure.
The Company also applies its technology and knowledge to cancer
cure and therapeutics research.
Safe-Harbor Statement
This release contains statements or projections regarding future
performance that are forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those projected as a result of certain
risks and uncertainties. The company's filings contain various RISK
FACTORS (and are incorporated herein by reference) and should be
read before any investment decision.
ChromoCure, Inc. www.ChromoCure.com info@chromocure.com Tel
1.775.636.6548
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 5 2024 まで 6 2024
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Chromocure Inc (CE) (その他OTC): 0 recent articles
その他のChromoCure, Inc.ニュース記事